Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rigel Pharmaceuticals, Inc.    RIGL

RIGEL PHARMACEUTICALS, INC.

(RIGL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2019 06/20/2019 06/21/2019 06/24/2019 06/25/2019 Date
2.29(c) 2.27(c) 2.3(c) 2.21(c) 2.22(c) Last
603 039 650 668 3 304 459 754 603 631 478 Volume
-2.14% -0.87% +1.32% -3.91% +0.45% Change
More quotes
Financials (USD)
Sales 2019 82,6 M
EBIT 2019 -56,2 M
Net income 2019 -54,4 M
Finance 2019 121 M
Yield 2019 -
Sales 2020 84,9 M
EBIT 2020 -67,9 M
Net income 2020 -66,3 M
Finance 2020 138 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 3,01x
EV / Sales2020 2,73x
Capitalization 369 M
More Financials
Company
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses... 
More about the company
Surperformance© ratings of Rigel Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on RIGEL PHARMACEUTICALS, INC
06/14RIGEL PHARMACEUTICALS : to Present Two Posters Highlighting Fostamatinib at the ..
AQ
06/13RIGEL PHARMACEUTICALS : to Present Two Posters Highlighting Fostamatinib at the ..
PR
05/31RIGEL PHARMACEUTICALS : to Present at Jefferies 2019 Healthcare Conference
PR
05/24RIGEL PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submissio..
AQ
05/16RIGEL PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
05/16RIGEL PHARMACEUTICALS : Enrolls First Patient in Phase 3 Clinical Trial of Fosta..
PR
05/07RIGEL : 1Q Earnings Snapshot
AQ
05/07RIGEL PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
AQ
05/07RIGEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
05/07RIGEL PHARMACEUTICALS : Announces First Quarter 2019 Financial Results and Provi..
PR
More news
Sector news : Bio Therapeutic Drugs
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Bio Therapeutic Drugs
Chart RIGEL PHARMACEUTICALS, INC.
Duration : Period :
Rigel Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RIGEL PHARMACEUTICALS, INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 8,33 $
Spread / Average Target 277%
EPS Revisions
Managers
NameTitle
Raul R. Rodriguez President & Chief Executive Officer
Gary A. Lyons Chairman
Dean L. Schorno Chief Financial Officer & Executive Vice President
Anne-Marie S. Duliege Chief Medical Officer & Executive Vice President
Peter S. Ringrose Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RIGEL PHARMACEUTICALS, INC.-3.48%358
GILEAD SCIENCES10.06%80 909
VERTEX PHARMACEUTICALS9.24%42 680
REGENERON PHARMACEUTICALS-16.32%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC16.69%8 523